{
      "Rank": 375,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [
            "No"
      ],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [
            "Yes"
      ],
      "ArmGroupDescription": [],
      "ArmGroupInterventionName": [
            "Drug: AstroStem",
            "Other: Placebo-Control"
      ],
      "ArmGroupLabel": [
            "AstroStem",
            "Placebo-Control"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [
            "Female",
            "Male"
      ],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03117738"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [
            "Hispanic or Latino",
            "Not-Hispanic or Latino",
            "White",
            "Black or African American",
            "Asian",
            "American Indian or Alaska Native",
            "Native Hawaiian or Other Pacific Islander",
            "Other"
      ],
      "BaselineDenomCountGroupId": [
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineDenomCountValue": [
            "11",
            "10",
            "21"
      ],
      "BaselineDenomUnits": [
            "Participants"
      ],
      "BaselineGroupDescription": [
            "AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)",
            "Placebo-Control: Saline with 30% auto-serum",
            "Total of all reporting groups"
      ],
      "BaselineGroupId": [
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineGroupTitle": [
            "AstroStem",
            "Placebo-Control",
            "Total"
      ],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation"
      ],
      "BaselineMeasureParamType": [
            "Mean",
            "Count of Participants",
            "Count of Participants",
            "Mean",
            "Mean",
            "Mean"
      ],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [
            "Age, Continuous",
            "Sex: Female, Male",
            "Race/Ethnicity, Customized",
            "Height",
            "Weight",
            "BMI"
      ],
      "BaselineMeasureUnitOfMeasure": [
            "years",
            "Participants",
            "Participants",
            "cm",
            "kg",
            "kg/m^2"
      ],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [
            "7.6",
            "8.2",
            "7.6",
            "14.4",
            "9.7",
            "12.1",
            "17.2",
            "12.0",
            "15.5",
            "4.3",
            "3.5",
            "4.3"
      ],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [
            "72.4",
            "75.6",
            "73.9",
            "4",
            "5",
            "9",
            "7",
            "5",
            "12",
            "2",
            "1",
            "3",
            "9",
            "9",
            "18",
            "10",
            "9",
            "19",
            "0",
            "0",
            "0",
            "1",
            "1",
            "2",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "167.9",
            "168.3",
            "168.1",
            "74.8",
            "64.6",
            "69.9",
            "26.3",
            "22.8",
            "24.6"
      ],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This is a randomized, double-blind, placebo-controlled, parallel-group comparison study in subjects with Alzheimer's Disease. Following first screening period, subjects will be randomly assigned into one of the following arms: AstroStem and placebo control in a 1:1 ratio. AstroStem or placebo control will be administered via I.V. at Week 0. This procedure will be repeated 9 times at 2-week interval. Subjects will be scheduled for two follow-up visits at Weeks 30 and 52 to evaluate primary and secondary outcome endpoints."
      ],
      "BriefTitle": [
            "A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "August 31, 2019"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Alzheimer Disease"
      ],
      "ConditionAncestorId": [
            "D000003704",
            "D000001927",
            "D000002493",
            "D000009422",
            "D000024801",
            "D000019636",
            "D000019965",
            "D000001523"
      ],
      "ConditionAncestorTerm": [
            "Dementia",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Nervous System Diseases",
            "Tauopathies",
            "Neurodegenerative Diseases",
            "Neurocognitive Disorders",
            "Mental Disorders"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC10",
            "BXM",
            "All",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Nervous System Diseases",
            "Behaviors and Mental Disorders",
            "All Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Alzheimer's Disease",
            "Alzheimer's Disease"
      ],
      "ConditionBrowseLeafId": [
            "M3037",
            "M6056",
            "M4356",
            "M4894",
            "M22155",
            "M20711",
            "M20989",
            "M13625",
            "M3967",
            "T2192"
      ],
      "ConditionBrowseLeafName": [
            "Alzheimer Disease",
            "Dementia",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Tauopathies",
            "Neurodegenerative Diseases",
            "Neurocognitive Disorders",
            "Psychotic Disorders",
            "Mental Disorders",
            "Familial Alzheimer Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high"
      ],
      "ConditionMeshId": [
            "D000000544"
      ],
      "ConditionMeshTerm": [
            "Alzheimer Disease"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Triple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nMale or female subjects aged 50 and above at the time of signing the Informed Consent form\nSubjects who can understand and provide written informed consent (assent)\nSubjects who have diagnosis of probable mild-to-moderate Alzheimer disease according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke; Alzheimer's Disease and Related Disorders Association) criteria\nSubjects who have MMSE Score of 16 to 26 at screening\nSubjects who are taking FDA-approved AD medications (donepezil, galantamine, memantine, rivastigmine or their combinations) treatment on a stable dosage for at least 3 months prior to screening.\nSubjects who have one (or more) identified adult caregiver who is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for \u22652 hours/day \u22654 days/week; and agrees to accompany the subject to each study visit\nSubjects who have a designated study partner who will accompany the subject to all clinic visits and participate in the subject's clinical assessments\n\nExclusion Criteria:\n\nSubjects who are females who are pregnant, nursing, or of childbearing potential while not practicing effective contraception\nSubjects who have signs of delirium\nSubjects who have had cortical stroke within the preceding 2 years\nSubjects who have a prolonged QTc interval; >450 msec in male or >470 msec in female at screening\nSubjects who have diagnosis of severe white matter hyperintensity (WMH), which is defined as \u2265 25mm of the deep white matter and \u2265 10mm of the periventricular capping/banding in lengths\nSubjects who have diagnosis of dementia or cause of cognitive impairment other than Alzheimer's disease\nSubjects who have a significant abnormal result in laboratory tests, in the opinion of the investigator\nSubjects who have participated in any investigational drug, stem cell therapy, or device trial within the previous 3 months at screening\nSubjects with any current psychiatric diagnosis other than AD if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the subject\u00b4s ability to complete the study\nSubjects who are known to have autosomal dominant mutation-associated presenile AD\nSubjects who show signs of AIDS (Acquired Immunodeficiency Syndrome), HBV (Hepatitis B Virus), HCV (Hepatitis C), VDRL (Venereal Disease Research Laboratory)\nSubjects who have any conditions that would contraindicate an MRI, such as the presence metallic objects in the eyes, skin, or heart\nSubjects who have > 4 cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as \"possible\" or \"definite\"), a single area of superficial siderosis, or evidence of a prior microhemorrhage as assessed by MRI\nSubjects who have history of malignant cancer within the last 5 years (The following is a partial list of conditions that are permissible for study entry: non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical, or non-progressive prostate cancer)\nSubjects who have suspected active lung disease based on chest X-ray\nSubjects who are hypersensitive to fetal bovine serum or penicillin\nSubjects who are currently using immunosuppressants, cytotoxic drug, corticosteroids or similar steroidal anti-inflammatory medication (e.g., Prednisone) on a regular basis (exceptions allowed include; regular use of steroidal nasal sprays, topical steroids, and estrogen-replacement therapy)\nSubjects for whom the investigator judges the liposuction can cause any problems\nSubjects who have history of local anesthetic allergy"
      ],
      "EnrollmentCount": [
            "21"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [
            "0",
            "0"
      ],
      "EventGroupDeathsNumAtRisk": [
            "11",
            "10"
      ],
      "EventGroupDescription": [
            "AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)",
            "Placebo-Control: Saline with 30% auto-serum"
      ],
      "EventGroupId": [
            "EG000",
            "EG001"
      ],
      "EventGroupOtherNumAffected": [
            "3",
            "2"
      ],
      "EventGroupOtherNumAtRisk": [
            "11",
            "10"
      ],
      "EventGroupSeriousNumAffected": [
            "3",
            "1"
      ],
      "EventGroupSeriousNumAtRisk": [
            "11",
            "10"
      ],
      "EventGroupTitle": [
            "AstroStem",
            "Placebo-Control"
      ],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [
            "0"
      ],
      "EventsTimeFrame": [
            "52 weeks"
      ],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001"
      ],
      "FlowAchievementNumSubjects": [
            "11",
            "10",
            "7",
            "5",
            "4",
            "5"
      ],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [
            "Withdrawal by Subject",
            "Lost to Follow-up"
      ],
      "FlowGroupDescription": [
            "AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC) 2x10e8 cells",
            "Saline with 30% auto-serum"
      ],
      "FlowGroupId": [
            "FG000",
            "FG001"
      ],
      "FlowGroupTitle": [
            "AstroStem",
            "Placebo-Control"
      ],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [
            "STARTED",
            "COMPLETED",
            "NOT COMPLETED"
      ],
      "FlowPeriodTitle": [
            "Overall Study"
      ],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [
            "FG000",
            "FG001",
            "FG000",
            "FG001"
      ],
      "FlowReasonNumSubjects": [
            "3",
            "1",
            "1",
            "4"
      ],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "Undecided"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "AstroStem",
            "Placebo-Control"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Autologous adipose tissue derived mesenchymal stem cells (AdMSC)",
            "Saline with 30% auto-serum"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "AstroStem",
            "Placebo-Control"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Drug",
            "Other"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [
            "March 4, 2019",
            "July 10, 2019",
            "June 26, 2017"
      ],
      "LargeDocFilename": [
            "Prot_000.pdf",
            "SAP_001.pdf",
            "ICF_002.pdf"
      ],
      "LargeDocHasICF": [
            "No",
            "No",
            "Yes"
      ],
      "LargeDocHasProtocol": [
            "Yes",
            "No",
            "No"
      ],
      "LargeDocHasSAP": [
            "No",
            "Yes",
            "No"
      ],
      "LargeDocLabel": [
            "Study Protocol",
            "Statistical Analysis Plan",
            "Informed Consent Form"
      ],
      "LargeDocTypeAbbrev": [
            "Prot",
            "SAP",
            "ICF"
      ],
      "LargeDocUploadDate": [
            "06/17/2021 03:10",
            "06/17/2021 05:05",
            "06/17/2021 03:12"
      ],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "August 10, 2021"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "August 7, 2021"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Nature Cell Co. Ltd."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Costa Mesa",
            "Santa Ana",
            "Honolulu"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States"
      ],
      "LocationFacility": [
            "ATP Clinical Research",
            "Syrentis Clinical Research",
            "Valden Medical"
      ],
      "LocationState": [
            "California",
            "California",
            "Hawaii"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "92626",
            "92705",
            "96817"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "50 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AstroStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Patients With Alzheimer's Disease"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Nature Cell Co. Ltd."
      ],
      "OrgStudyId": [
            "AST-ADP2-US01"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment"
      ],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [
            "Eye disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "General disorders",
            "General disorders",
            "General disorders",
            "General disorders",
            "General disorders",
            "Injury, poisoning and procedural complications",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Nervous system disorders",
            "Psychiatric disorders",
            "Skin and subcutaneous tissue disorders",
            "Infections and infestations",
            "Infections and infestations"
      ],
      "OtherEventSourceVocabulary": [
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1"
      ],
      "OtherEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001"
      ],
      "OtherEventStatsNumAffected": [
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "1",
            "1",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1"
      ],
      "OtherEventStatsNumAtRisk": [
            "11",
            "10",
            "11",
            "10",
            "11",
            "10",
            "11",
            "10",
            "11",
            "10",
            "11",
            "10",
            "11",
            "10",
            "11",
            "10",
            "11",
            "10",
            "11",
            "10",
            "11",
            "10",
            "11",
            "10",
            "11",
            "10",
            "11",
            "10",
            "11",
            "10",
            "11",
            "10",
            "11",
            "10"
      ],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [
            "Open Angle Glaucoma",
            "Dysphagia",
            "Gastrointestinal Reflux Disease",
            "Fatigue",
            "Infusion Site Reaction",
            "Oedema Peripheral",
            "Pain",
            "Pyrexia",
            "Fall",
            "Dehydration",
            "Abnormal Loss of Weight",
            "Hypokalaemia",
            "Syncope",
            "Agitation",
            "Ecchymosis",
            "Nasopharyngitis",
            "Pneumonia"
      ],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeDenomCountValue": [
            "11",
            "10",
            "7",
            "7",
            "7",
            "7",
            "7",
            "7",
            "7",
            "7",
            "7",
            "7",
            "7",
            "7",
            "11",
            "10"
      ],
      "OutcomeDenomUnits": [
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "OutcomeGroupDescription": [
            "AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)",
            "Placebo-Control: Saline with 30% auto-serum",
            "AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)",
            "Placebo-Control: Saline with 30% auto-serum",
            "AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)",
            "Placebo-Control: Saline with 30% auto-serum",
            "AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)",
            "Placebo-Control: Saline with 30% auto-serum",
            "AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)",
            "Placebo-Control: Saline with 30% auto-serum",
            "AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)",
            "Placebo-Control: Saline with 30% auto-serum",
            "AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)",
            "Placebo-Control: Saline with 30% auto-serum",
            "AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)",
            "Placebo-Control: Saline with 30% auto-serum"
      ],
      "OutcomeGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeGroupTitle": [
            "AstroStem",
            "Placebo-Control",
            "AstroStem",
            "Placebo-Control",
            "AstroStem",
            "Placebo-Control",
            "AstroStem",
            "Placebo-Control",
            "AstroStem",
            "Placebo-Control",
            "AstroStem",
            "Placebo-Control",
            "AstroStem",
            "Placebo-Control",
            "AstroStem",
            "Placebo-Control"
      ],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [
            "Number of subjects with treatment related adverse events as assessed by analysis of adverse events including symptoms, and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results",
            "Change of ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale) from Baseline at Week 30 Score range: 0-70 A score of 70 represents the most severe impairment and 0 represents the least impairment",
            "Change of MMSE from baseline at Week 30 Score range: 0-30 A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.",
            "Changes of CDR-SOB from baseline at Week 30 Score range: 0-18.0 0 = normal, 0.5-4.0 = questionable cognitive dementia, 4.5-9.0 = mild dementia, 9.5-15.5 = moderate dementia, and 16.0-18.0 = severe dementia",
            "Changes of NPI from baseline at Week 30 Score range: 0-144 higher score indicates higher disturbance.",
            "Changes of GDS from baseline at Week 30 Score range: 0-15 Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.",
            "Change of ADCS-ADL from baseline at Week 30 Score range: 0-78 Lower score indicates greater severity.",
            "Changes of C-SSRS from baseline at Week 30 Score range: 0-25 Higher score indicates higher severity."
      ],
      "OutcomeMeasureDispersionType": [
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation"
      ],
      "OutcomeMeasureParamType": [
            "Count of Participants",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean"
      ],
      "OutcomeMeasurePopulationDescription": [
            "3 of the 11 astrostem groups were dropped out and 1 was violated protocol.\n\n1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.",
            "3 of the 11 astrostem groups were dropped out and 1 was violated protocol.\n\n1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.",
            "3 of the 11 astrostem groups were dropped out and 1 was violated protocol.\n\n1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.",
            "3 of the 11 astrostem groups were dropped out and 1 was violated protocol.\n\n1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.",
            "3 of the 11 astrostem groups were dropped out and 1 was violated protocol.\n\n1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.",
            "3 of the 11 astrostem groups were dropped out and 1 was violated protocol.\n\n1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol."
      ],
      "OutcomeMeasureReportingStatus": [
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted"
      ],
      "OutcomeMeasureTimeFrame": [
            "30 Weeks",
            "Baseline and 30 Weeks",
            "Baseline and 30 Weeks",
            "Baseline and 30 Weeks",
            "Baseline and 30 Weeks",
            "Baseline and 30 Weeks",
            "Baseline and 30 Weeks",
            "Baseline and 30 Weeks"
      ],
      "OutcomeMeasureTitle": [
            "Treatment Related Adverse Events",
            "ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)",
            "MMSE (Mini-mental Status Examination)",
            "CDR-SOB (Clinical Dementia Rating-Sum of Boxes)",
            "NPI (Neuropsychiatric Inventory)",
            "GDS (Geriatric Depression Scale)",
            "ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)",
            "C-SSRS (Columbia Suicide Severity Rating Scale)"
      ],
      "OutcomeMeasureType": [
            "Primary",
            "Primary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary"
      ],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [
            "Participants",
            "score on a scale",
            "score on a scale",
            "score on a scale",
            "score on a scale",
            "score on a scale",
            "score on a scale",
            "score on a scale"
      ],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [
            "6.8",
            "5.4",
            "2.8",
            "2.8",
            "1.7",
            "1.5",
            "8.5",
            "11.5",
            "1.3",
            "2.1",
            "9.0",
            "9.8",
            "6.6",
            "0.0"
      ],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [
            "6",
            "3",
            "5.9",
            "3.0",
            "-3.4",
            "-1.4",
            "1.3",
            "0.9",
            "-1.4",
            "-5.7",
            "-0.3",
            "0.3",
            "-4.4",
            "-4.7",
            "-2.1",
            "0.0"
      ],
      "OverallOfficialAffiliation": [],
      "OverallOfficialName": [],
      "OverallOfficialRole": [],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [
            "tin50@stemcellbio.com"
      ],
      "PointOfContactOrganization": [
            "Nature Cell co., ltd"
      ],
      "PointOfContactPhone": [
            "02-545-4137"
      ],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [
            "Project Manager"
      ],
      "PrimaryCompletionDate": [
            "June 26, 2019"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Number of subjects with treatment related adverse events as assessed by analysis of adverse events including symptoms, and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results",
            "Change of ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale) from Baseline at Week 30 Score range: 0-70 A score of 70 represents the most severe impairment and 0 represents the least impairment"
      ],
      "PrimaryOutcomeMeasure": [
            "Treatment Related Adverse Events",
            "ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "30 Weeks",
            "Baseline and 30 Weeks"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [
            "July 9, 2021"
      ],
      "ResultsFirstPostDateType": [
            "Actual"
      ],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [
            "June 17, 2021"
      ],
      "ResultsFirstSubmitQCDate": [
            "June 17, 2021"
      ],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Change of MMSE from baseline at Week 30 Score range: 0-30 A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.",
            "Changes of CDR-SOB from baseline at Week 30 Score range: 0-18.0 0 = normal, 0.5-4.0 = questionable cognitive dementia, 4.5-9.0 = mild dementia, 9.5-15.5 = moderate dementia, and 16.0-18.0 = severe dementia",
            "Changes of NPI from baseline at Week 30 Score range: 0-144 higher score indicates higher disturbance.",
            "Changes of GDS from baseline at Week 30 Score range: 0-15 Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.",
            "Change of ADCS-ADL from baseline at Week 30 Score range: 0-78 Lower score indicates greater severity.",
            "Changes of C-SSRS from baseline at Week 30 Score range: 0-25 Higher score indicates higher severity."
      ],
      "SecondaryOutcomeMeasure": [
            "MMSE (Mini-mental Status Examination)",
            "CDR-SOB (Clinical Dementia Rating-Sum of Boxes)",
            "NPI (Neuropsychiatric Inventory)",
            "GDS (Geriatric Depression Scale)",
            "ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)",
            "C-SSRS (Columbia Suicide Severity Rating Scale)"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Baseline and 30 Weeks",
            "Baseline and 30 Weeks",
            "Baseline and 30 Weeks",
            "Baseline and 30 Weeks",
            "Baseline and 30 Weeks",
            "Baseline and 30 Weeks"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment"
      ],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [
            "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "Gastrointestinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Infections and infestations"
      ],
      "SeriousEventSourceVocabulary": [
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1",
            "MedDRA 18.1"
      ],
      "SeriousEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001"
      ],
      "SeriousEventStatsNumAffected": [
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1"
      ],
      "SeriousEventStatsNumAtRisk": [
            "11",
            "10",
            "11",
            "10",
            "11",
            "10",
            "11",
            "10"
      ],
      "SeriousEventStatsNumEvents": [
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1"
      ],
      "SeriousEventTerm": [
            "oesophageal squamous cell carcinoma stage IV",
            "diarrhea",
            "pulmonary embolism",
            "Acute Pulmonary Oedema"
      ],
      "StartDate": [
            "May 9, 2017"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "June 2021"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "April 18, 2017"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "April 10, 2017"
      ],
      "StudyFirstSubmitQCDate": [
            "April 12, 2017"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}